



03-15-2002

FORM PTO-1594

RE



U.S. Department of Commerce
Patent and Trademark Office
Attorney Docket No. 8689.0061

102017674

To the Honorable Commissioner of Patents and Trademarks, Patent and Trademark Office, for the attached original documents or copy thereof.

1. Name(s) of conveying party(ies):
Principia Pharmaceutical Corporation **3-4-02**

Individual(s)
 Association
 Limited Partnership
 Corporation
 General Partnership
 Other:

Additional name(s) of conveying party(ies) attached? Yes No

2. Name(s) and address(es) of receiving party(ies):

Name: Human Genome Sciences, Inc.

Address: 9410 Key West Avenue
Rockville, Maryland 20850

Individual(s)
 Association
 General Partnership
 Limited Partnership
 Corporation of Delaware
 Other:

If assignee is not domiciled in the United States, a domestic representative is attached: Yes No

(Designation must be a separate document from Assignment)

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:

Assignment
 Merger
 Security Agreement
 Change of Name
 Other:

Execution Date: February 22, 2002

4. Application number(s) or registration number(s):

A. Trademark Application Number(s):

76/081,992 - ALBUFERON
75/918,555 - PRINCIPIA
76/081,975 - ALBUTROPIN
75/918,554 - PRINCIPIA & Design

Additional numbers attached? Yes No

B. Trademark Registration Number(s):

None

Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Christie Baty Heinze

Address: FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3515

03/14/2002 DBYRNE 00000088 76081992

6. Total number of applications and registrations involved: 4

7. Total fee (37 CFR 3.41): \$115.00

Enclosed
 Authorized to be charged to deposit account
 Authorized to be charged to deposit account only if fee is deficient

8. Deposit Account No.: 06-0916

01 FC:481 40.00 OP
02 FC:482 75.00 OP

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Christie Baty Heinze Christie Baty Heinze March 8, 2002
Name of person signing Signature Date

Total number of pages including cover sheet, attachments and documents: 4


ASSIGNMENT

Principia Pharmaceutical Corporation, a corporation organized and existing under the laws of the State of Delaware, U.S.A., with its principal place of business at 2650 Eisenhower Avenue, Norristown, Pennsylvania 19403 ("Assignor"), is the owner of the trademarks identified in Exhibit A and of the trademark applications and registrations therefor ("the Trademarks").

Human Genome Sciences, Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A., with its principal place of business at 9410 Key West Avenue, Rockville, Maryland 20850 ("Assignee"), wishes to acquire the Trademarks.

In consideration of the foregoing and for other good and valuable consideration, receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee all its right, title, and interest in and to the Trademarks, together with the goodwill of the business associated with the Trademarks, and the right to sue and recover for past infringements, dilution, and other violations.

PRINCIPIA PHARMACEUTICAL CORPORATION
(ASSIGNOR)


By: 
Craig Rosen
Vice President

Sworn to and subscribed before me this 22nd day of February, 2002.


Notary Public

My Commission Expires: ~~_____~~ **ROSE HADIDIAN**
NOTARY PUBLIC STATE OF MARYLAND
My Commission Expires July 20, 2005

HUMAN GENOME SCIENCES, INC. (ASSIGNEE)

By: 
Craig Rosen
Executive Vice President

Sworn to and subscribed before me this 22nd day of February, 2002.


Notary Public

My Commission Expires: ~~_____~~ **ROSE HADIDIAN**
NOTARY PUBLIC STATE OF MARYLAND
My Commission Expires July 20, 2005

106515_1.DOC

EXHIBIT A

Registrations

<u>COUNTRY</u>	<u>MARK</u>	<u>REG. NO.</u>	<u>REG. DATE</u>
Australia	ALBUFERON	861,526	7/9/2001
Japan	PRINCIPIA	4,516,179	10/19/2001
Japan	PRINCIPIA & Design	4,516,178	10/19/2001
Mexico	ALBUFERON	696,063	4/25/2001
New Zealand	ALBUFERON	629,648	6/21/2001
Switzerland	ALBUFERON	484,208	5/22/2001
Australia	ALBUTROPIN	861,523	7/9/2001
Switzerland	ALBUTROPIN	629,649	1/26/2001
Hong Kong	ALBUTROPIN	7780/200	7/4/2001
Norway	ALBUTROPIN	211,741	11/15/2001
New Zealand	ALBUTROPIN	629,649	6/30/2000

Applications

<u>COUNTRY</u>	<u>MARK</u>	<u>APP. NO.</u>	<u>APP. DATE</u>
Argentina	ALBUFERON	2,321,326	2/8/2000
Canada	ALBUFERON	1,086,957	12/20/2000
Canada	PRINCIPIA	1,068,763	7/27/2000
Canada	PRINCIPIA & Design	1,068,762	7/27/2000
China	ALBUFERON	2001 002327	1/2/2001
Czech Republic	ALBUFERON	162,724	12/27/2000
European Community	ALBUFERON	2,011,724	12/21/2001
European Community	PRINCIPIA	1,778,695	7/27/2000
European Community	PRINCIPIA & Design	1,779,974	7/27/2000

<u>COUNTRY</u>	<u>MARK</u>	<u>APP. NO.</u>	<u>APP. DATE</u>
Hungary	ALBUFERON	0006900	12/21/2000
Japan	ALBUFERON	2000-137623	12/21/2000
Argentina	ALBUTROPIN	2,321,327	12/21/2000
Canada	ALBUTROPIN	1,086,956	12/20/2000
Czech Republic	ALBUTROPIN	162,723	12/27/2000
European Community	ALBUTROPIN	2,012,607	12/21/2000
Hungary	ALBUTROPIN	M0006899	12/21/2000
Japan	ALBUTROPIN	2000-137622	12/21/2000
Mexico	ALBUTROPIN	464,920	1/8/2001
Poland	ALBUTROPIN	Z-229307	12/20/2000
Republic of Korea	ALBUFERON	2000-59068	12/22/2000
Republic of Korea	ALBUTROPIN	2000-59069	12/22/2000
Russian Federation	ALBUFERON	2000-732945	12/21/2000
Slovenia	ALBUTROPIN	Z200071999	12/22/2000
Taiwan	ALBUFERON	89074765	12/26/2000
Taiwan	ALBUTROPIN	89074766	12/26/2000
Turkey	ALBUFERON	113879/20	12/22/2000
Turkey	ALBUTROPIN	113879/20	12/22/2000
United States	ALBUFERON	76/081,992	6/30/00
United States	PRINCIPIA	75/918,555	2/15/00
United States	ALBUTROPIN	76/081,975	6/30/00
United States	PRINCIPIA & DESIGN	75/918,554	2/15/00